EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 374 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $353,992 | +1.2% | 16,201 | -11.5% | 0.22% | +3.9% |
| Q2 2023 | $349,656 | -5.3% | 18,297 | -3.8% | 0.21% | +2.0% |
| Q1 2023 | $369,295 | +23.2% | 19,026 | +1.8% | 0.20% | +29.3% |
| Q4 2022 | $299,756 | +43.4% | 18,688 | +40.2% | 0.16% | +89.2% |
| Q3 2022 | $209,000 | -23.4% | 13,327 | +1.5% | 0.08% | -17.8% |
| Q2 2022 | $273,000 | -45.0% | 13,133 | -40.0% | 0.10% | -54.5% |
| Q1 2022 | $496,000 | +24.0% | 21,880 | 0.0% | 0.22% | +47.0% |
| Q4 2021 | $400,000 | -5.9% | 21,880 | +8.9% | 0.15% | -19.3% |
| Q3 2021 | $425,000 | +6.2% | 20,097 | -8.4% | 0.19% | +14.0% |
| Q2 2021 | $400,000 | -41.8% | 21,937 | -27.9% | 0.16% | -43.4% |
| Q1 2021 | $687,000 | +15.7% | 30,432 | +2.8% | 0.29% | +17.4% |
| Q4 2020 | $594,000 | -6.9% | 29,602 | +13.4% | 0.25% | -26.3% |
| Q3 2020 | $638,000 | +12.3% | 26,104 | +9.2% | 0.34% | +24.5% |
| Q2 2020 | $568,000 | -0.2% | 23,905 | -27.6% | 0.27% | +15.0% |
| Q1 2020 | $569,000 | -9.8% | 33,024 | -7.8% | 0.23% | +127.2% |
| Q4 2019 | $631,000 | +1.4% | 35,810 | +1.8% | 0.10% | -17.6% |
| Q3 2019 | $622,000 | -29.2% | 35,178 | -14.4% | 0.12% | -32.4% |
| Q2 2019 | $878,000 | +1.3% | 41,091 | +12.8% | 0.18% | -90.0% |
| Q1 2019 | $867,000 | +52.9% | 36,441 | +26.5% | 1.84% | +1802.1% |
| Q4 2018 | $567,000 | -19.7% | 28,817 | -27.7% | 0.10% | +32.9% |
| Q3 2018 | $706,000 | -11.6% | 39,851 | +7.3% | 0.07% | -89.7% |
| Q2 2018 | $799,000 | +4.6% | 37,132 | +7.7% | 0.71% | +6.5% |
| Q1 2018 | $764,000 | -31.2% | 34,479 | -5.6% | 0.66% | -52.4% |
| Q4 2017 | $1,110,000 | -12.9% | 36,522 | -30.6% | 1.39% | +709.9% |
| Q3 2017 | $1,275,000 | -1.6% | 52,621 | 0.0% | 0.17% | -10.9% |
| Q2 2017 | $1,296,000 | -5.7% | 52,621 | -17.1% | 0.19% | -21.2% |
| Q1 2017 | $1,375,000 | +60.8% | 63,443 | +10.6% | 0.24% | -3.9% |
| Q4 2016 | $855,000 | -21.3% | 57,343 | -32.5% | 0.26% | -51.4% |
| Q3 2016 | $1,086,000 | +87.2% | 84,932 | +14.4% | 0.52% | +22.1% |
| Q2 2016 | $580,000 | +26.6% | 74,230 | -35.1% | 0.43% | -31.9% |
| Q1 2016 | $458,000 | – | 114,429 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |